EGFR and non-small cell lung carcinoma: MET activation is a very well-known bypass signaling pathway in EGFR-mutant NSCLC but in ALK-rearranged NSCLC does not cause resistance to the first-generation TKI crizotinib, which is also a potent MET inhibitor [186,187].